TNBC and Immunotherapy: Key Applications for Pathologists
 
This activity is designed to help pathologists and laboratory professionals learn how PD-L1 testing and interpretation is performed in patients with advanced triple negative breast cancer (TNBC). Panelists will also discuss key considerations when assessing pathological complete response (pCR) following neoadjuvant therapy.  
Provided by the American Society for Clinical Pathology in partnership with Q Synthesis LLC.
 
The activity offers 0.5 CME/CMLE credit.
 
Target Audience
This activity has been designed to meet the educational needs of pathologists and laboratory professionals diagnosing cancer.
 
Activity Agenda

• Introductions
• Review when and how PD-L1 testing is performed in TNBC
• Panel discussion: considerations when assessing pathological response following neoadjuvant therapy
• Summary of key takeaways  

Faculty/Authors

Marilin Rosa, MD  
Senior Member, Moffitt Cancer Center and Research Institute 
Professor, University of South Florida Tampa, Florida 
Section Head of Breast Pathology 
Director of the Breast Pathology Fellowship at Moffitt 
 
Huina Zhang, MD, PhD  
Associate Professor - Department of Pathology and Laboratory Medicine (SMD) 
University of Rochester Medical Center, Rochester, NY 
 
Lamees Saeed, MD   
Breast and Molecular Pathology Fellow at Moffitt Cancer Center 
 
Joseph Kim, MD  
President of Q Synthesis LLC 

Accreditation Statement
The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. 

Physician's Competency: Patient Care, Medical Knowledge, Practice-Based Learning and Improvement

CME/CMLE Credit: 0.5
Estimated Completion Time: 0.5 hour
Format: Online educational activity

Credit Designation Statement
The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
 
The ASCP designates this activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
 
ASCP designates this activity for a maximum of 0.5 CMLE credit.  This activity meets CMP and state re-licensure requirements for laboratory personnel.
 
For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, during normal business hours: Monday through Friday, 8 a.m. to 6 p.m. Eastern Time 

Method of Participation
To complete the activity and receive credit, the participant must complete the online activity. CME certificates will be provided online. 
 
Commercial Support
This activity is funded by an independent educational grant from Merck. 

Instructions

To claim CME/CMLE credit for the exercise, do the following:

1. Review the Technical Considerations.
2. Click Go to Content and click the first module of the course.
3. Complete the Demographic Survey.
4. Complete the Pre-Test.
5. Review the Educational Activity.
6. Complete and submit the Post Exam. You will have a maximum of three attempts to obtain the required score. You will be notified if you have met the credit requirements after each attempt.
7. Submit the course Evaluation.
8. Enter the maximum number of credits offered and click Claim CME/CMLE to register credit.

Upon completion of this activity, you will be able to:

• Describe the role of PD-L1 testing in triple-negative breast cancer (TNBC).

• Discuss recent advances in neoadjuvant immunotherapy for patients with TNBC.

• Summarize how pathological response is assessed in patients with breast cancer who receive neoadjuvant therapy.